Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia

Abstract

Amisulpride is an atypical antipsychotic, which has demonstrated efficacy across the range of symptoms of schizophrenia. This study compares the treatment costs of amisulpride (including drug costs, hospital costs, and costs of clinician and nurse visits) with those of risperidone over a 6-month treatment period, from the perspective of the UK National Health Service. Resource utilisation data were collected alongside an international, multicentre clinical trial comparing amisulpride (400-1000 mg/day) with risperidone (4-10 mg/day) in 198 patients with schizophrenia. As this trial demonstrated that amisulpride had at least equivalent efficacy to risperidone, the present study was a cost-minimisation analysis. Unit cost data for the UK were obtained from published sources and applied to the clinical data to calculate direct treatment costs. Amisulpride was associated with lower drug acquisition costs and lower resource utilisation costs than risperidone, although the differences did not reach statistical significance. Overall, the average total cost per patient for 6 months of treatment with amisulpride (£12,673; 95% CI: 10,628, 14,717) was £2,145 less than for risperidone (£14,818; 95% CI: 12,323, 17,312). These findings are similar to those of a previous study that compared the treatment costs of amisulpride with those of haloperidol, and found that amisulpride was associated with significantly lower direct treatment costs than haloperidol. Amisulpride is a valuable treatment option in patients with Schizophrenia.